4.7 Review

Severity of COVID-19 and Treatment Strategy for Patient With Diabetes

期刊

FRONTIERS IN ENDOCRINOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.602735

关键词

Diabetes mellitus; COVID-19; SARS-CoV-2; cytokine storm; glycemic control

资金

  1. Department of Science and Technology of Liaoning province [2019-ZD-0774]

向作者/读者索取更多资源

COVID-19, named by WHO in February 2020, quickly became a global pandemic by March 2020, posing higher risks for patients with comorbidities like diabetes. Currently, there is no approved standard treatment protocol for COVID-19 cases with pre-existing diabetes.
Coronavirus disease 2019 (COVID-19), which was named by the World Health Organization (WHO) in February 2020, has quickly spread to more than 200 countries around the world and was declared as a global pandemic in March 2020. The severity of the disease makes it more prone to severe symptoms and higher mortality rates in patients, especially those who are with comorbidities, including high blood pressure, cardiovascular disease, obesity, and diabetes, increases the concern over the consequences of this pandemic. However, initial reports do not clearly describe whether diabetes itself or associated comorbidities or treatment strategies contribute to the severe prognosis of COVID-19 infections. Various clinical trials are being conducted on glucose-lowering agents but to date, there is no standard treatment protocol approved for COVID-19 cases with pre-existing diabetes. This review is aimed to decipher the potential risk factors of COVID-19 involved from existing evidence. Identification of a novel therapeutic strategy could be beneficial for combating SARS-CoV-2, which might be dreadful to debilitating people who have diabetes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据